

Supplementary information, Figure S5

A

Spleen

Primary BMT		Secondary BMT	
human CD45 †	16.3 ± 4.2	human CD45 †	7.7 ± 0.2
CD14 ‡	12.5 ± 5.1	CD14 ‡	20.0 ± 1.6
CD3 ‡	18.2 ± 3.0	CD3 ‡	14.3 ± 1.3
CD19 ‡	10.7 ± 4.3	CD19 ‡	5.5 ± 1.0

† Percentage in total mouse and human CD45 cells

‡ Percentage in total human CD45 cells

B

Primary BMT †		Secondary BMT †	
Adipose ts.	67.7 ± 12.4	Adipose ts.	50.2 ± 10.8
Kidney	83.4 ± 4.4	Kidney	69.0 ± 4.7
Liver	51.1 ± 4.9	Liver	61.8 ± 6.2
Lymph node	59.1 ± 12.3	Lymph node	83.1 ± 9.3

† Percentage in total mouse and human CD45 cells

FigureS5. BBHS-derived HSPC engraftment of solid organs. (A) Hematopoietic chimerism and hematopoietic lineage composition of splenocytes in primary (n=4) and secondary BMT (n=2) (B) Human hematopoietic cell chimerism of mononuclear cell derived from potential homing sites (adipose tissue, kidney, liver and lymph nodes) 12 weeks after primary and secondary BMT. Numbers indicate the mean ± S.E.M of each experiment.